Compare Gemini Space Station Inc (GEMI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Novartis AG — how do they compare? Gemini Space Station Inc trades at $4.45 (market cap $582.14M), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 470.7× Gemini Space Station Inc's market cap, and Novartis AG pays a 3.31% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Novartis AG for 82 Days on average.
| GEMI | NVS | |
|---|---|---|
Market Cap | $582.14M | $274.00B |
Volume | 1,995,802 | 1,852,137 |
Sector | Financials | Health |
52-Week High | $25.41 | $168.62 |
52-Week Low | $3.54 | $121.80 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | $561.16M | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.49, down 3.85% today, with a bearish technical signal despite oversold RSI readings. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$517 million. Recent news highlights expansion into commission-free stock trading and prediction markets, though the stock faces class action lawsuits alleging securities violations.
The outlook remains challenged by persistent losses and negative cash flow from operations, offset by financing activities. Analyst consensus is mixed with a $5.33 price target (48% upside), but high business execution and regulatory risks warrant caution. The stock's valuation appears stretched given profitability concerns, making it speculative for risk-tolerant investors.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
